866-997-4948(US-Canada Toll Free)

Ulcerative Colitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Dec 2010

Category :

Therapeutic Area

No. of Pages : 44 Pages


GlobalData, the industry analysis specialist, has released a new report, “Ulcerative Colitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global ulcerative colitis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Ulcerative Colitis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. 

GlobalData estimated the global Ulcerative Colitis (UC) market to be valued at $1.35 billion in 2009. It is estimated to grow at a reasonable CAGR of 5.9% annually for the next eight years to reach $2.14 billion by 2017. The growth will be driven by several factors, like intensification in UC prevalence, increasing awareness and expected approvals of biologics in the future. Barriers for the UC market include diagnostic limitations and a complex disease etiology, and these will moderately affect the growth of the market. These barriers can be overcome in due course with technological advances in the field of drug discovery and disease diagnosis. 

Scope

The report analyzes market opportunities and challenges in the global ulcerative colitis market. Its scope includes

  • Annual global ulcerative colitis market revenues data from 2001 to 2009, forecast forward for eight years to 2017.
  • Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include anti-inflammatory action, cytokine inhibitors, probiotics, Anti-T-cell, immunosuppressant and NSAIDs.
  • Analysis of the current and future market competition in the global ulcerative colitis market. Key market players covered are Abbott Laboratories, Takeda Pharmaceuticals, Pfizer Inc, Johnson & Johnson, Salix Pharmaceuticals.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with ulcerative colitis.
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global ulcerative colitis market.
  • Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global ulcerative colitis market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global ulcerative colitis market landscape? - identify, understand and capitalize.
Table of Content

1 Table of contents 3

1.1 List of Tables 5
1.2 List of Figures 5

2 Ulcerative Colitis Therapeutics: Introduction 6
2.1 GlobalData Pipeline Report Guidance 7

3 Ulcerative Colitis Therapeutics Market: Market Characterization 8
3.1 Overview 8
3.2 Ulcerative Colitis Therapeutics Market Size 8
3.3 Ulcerative Colitis Therapeutics Market Forecast and CAGR 9
3.4 Drivers and Barriers for Ulcerative Colitis Therapeutics Market 10
3.4.1 Drivers for Ulcerative Colitis Therapeutics Market 10
3.4.2 Barriers for Ulcerative Colitis Therapeutics Market 10
3.5 Opportunity and Unmet Need 11
3.6 Key Takeaway 12

4 Ulcerative Colitis Therapeutics Market Competitive Assessment 13
4.1 Overview 13
4.2 Strategic Competitor Assessment 13
4.3 Product Profile for the Major Marketed Products in Ulcerative Colitis Therapeutics Market 14
4.3.1 Asacol 14
4.3.2 Lialda 15
4.3.3 Pentasa 15
4.3.4 Apriso 16
4.3.5 Colazal 17
4.3.6 Remicade 17
4.3.7 Azulfidine 18
4.4 Key Takeaway 20

5 Ulcerative Colitis Therapeutics Market Pipeline Assessment 21
5.1 Overview 21
5.2 Strategic Pipeline Assessment 21
5.2.1 Technology Trends Analytic Framework 21
5.3 Ulcerative Colitis Therapeutics Market Promising Drugs Under Clinical Development 22
5.4 Molecule Profile for Promising Drugs under Clinical Development 23
5.4.1 Adalimumab 23
5.4.2 Golimumab 23
5.4.3 Vedolizumab 24
5.4.4 Ulcerative Colitis Therapeutics Market Clinical Pipeline by Mechanism of Action 25
5.5 Ulcerative Colitis Therapeutics Pipeline Pipeline by Clinical Phases of Development 26
5.5.1 Ulcerative Colitis Therapeutics Regulatory and Phase III Clinical Pipeline 26
5.5.2 Ulcerative Colitis Therapeutics Phase II Clinical Pipeline 27
5.5.3 Ulcerative Colitis Therapeutics Phase I/II Clinical Pipeline 27
5.5.4 Ulcerative Colitis Therapeutics Phase I Clinical Pipeline 28
5.5.5 Ulcerative Colitis Therapeutics Preclinical Pipeline 28
5.6 Key Takeaway 28
5.7 Ulcerative Colitis Therapeutics Market: Implications for Future Market Competition 29

6 Ulcerative Colitis Therapeutics Market Future Players in the Ulcerative Colitis Therapeutics Market 30
6.1 Introduction 30
6.2 The Takeda Oncology Company (Formerly Millennium Pharmaceuticals) 30
6.2.1 Overview 30
6.2.2 Business Description 31
6.2.3 Ulcerative Colitis Portfolio 31
6.3 Centocor Ortho Biotech, Inc 31
6.3.1 Overview 31
6.3.2 Business Description 32
6.3.3 Ulcerative Colitis Portfolio 32
6.4 Abbott Laboratories 33
6.4.1 Overview 33
6.4.2 Business Description 33
6.4.3 Autoimmune Diseases Portfolio 34
6.5 Pfizer Incorporated 34
6.5.1 Overview 34
6.5.2 Business Description 34
6.5.3 Autoimmune Diseases Portfolio 35
6.6 Salix Pharmaceuticals, Ltd 36
6.6.1 Overview 36
6.6.2 Business Description 36
6.6.3 Autoimmune Disease Portfolio 36

7 Ulcerative Colitis Therapeutics Market Appendix 38
7.1 Acronyms 38
7.2 Research Methodology 39
7.2.1 Coverage 39
7.2.2 Secondary Research 39
7.2.3 Forecasting 40
7.2.4 Primary Research 43
7.2.5 Expert Panels 43
7.3 Contact Us 43
7.4 Disclaimer 43
7.5 Sources 44

List of Table


Table 1: Ulcerative Colitis Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2009
Table 2: Ulcerative Colitis Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2017
Table 3: Major Marketed Products Comparison in Ulcerative Colitis Therapeutics Market , November 2009
Table 4: Ulcerative Colitis Therapeutics - Most Promising Drugs Under Clinical Development, 2009
Table 5: Ulcerative Colitis Therapeutics - Phase III Clinical Pipeline, 2009
Table 6: Ulcerative Colitis Therapeutics - Phase II Clinical Pipeline, 2009
Table 7: Ulcerative Colitis Therapeutics - Phase I/II Clinical Pipeline, 2009
Table 8: Ulcerative Colitis Therapeutics - Phase I Clinical Pipeline, 2009
Table 9: Ulcerative Colitis Therapeutics - Preclinical Pipeline, 2009
Table 10: Millennium (Takeda) - Ulcerative Colitis Therapeutics Pipeline, 2010
Table 11: Centocor (J&J) - Autoimmune Diseases Pipeline, 2009
Table 12: Centocor (J&J) - Ulcerative Colitis Therapeutics Pipeline, 2009
Table 13: Abbott - Autoimmune Diseases Therapeutics Pipeline, 2009
Table 14: Abbott - Ulcerative Colitis Therapeutics Pipeline, 2009
Table 15: Pfizer - Autoimmune Diseases Pipeline, 2009
Table 16: Pfizer - Ulcerative Colitis Therapeutics Pipeline, 2009
Table 17: Salix Pharmaceuticals - Autoimmune Diseases Pipeline, 2009
Table 18: Salix Pharamceuticals - Ulcerative Colitis Therapeutics Pipeline, 2009

List of Chart


Figure 1: Ulcerative Colitis, Global, Historical Revenue ($m), 2001-2009 8
Figure 2: Ulcerative Colitis, Global, Revenue Forecasts ($m), 2009-2017 9
Figure 3: Opportunity and Unmet Need in the Ulcerative Colitis Therapeutics Market, 2010 11
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Ulcerative Colitis, 2009 13
Figure 5: Technology Trends Analytic Framework of the Ulcerative Colitis Therapeutics Pipeline, 2009 21
Figure 6: Technology Trends Analytic Framework of the Ulcerative Colitis Therapeutics Pipeline Description, 2009 22
Figure 7: Ulcerative Colitis Therapeutics Market Clinical Pipeline by Mechanism of Action, 2009 25
Figure 8: Ulcerative Colitis Therapeutics Pipeline by Phase of Clinical Development, 2009 26
Figure 9: Implications for future market competition in the Ulcerative Colitis therapeutic market, 2010 29
Figure 10: Ulcerative Colitis Therapeutics Market Clinical Pipeline by Company, 2009 30
Figure 11: GlobalData Market Forecasting Model, 2010 42

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *